Johnson & Johnson's Fiscal Year is From January To December - All Figures are in USD, Billions.
The item "End-Period-Cash-Flow" stands at 99.39 Billion United States Dollars for the trailing twelve months (TTM) period ending 09/30/2025.
Johnson & Johnson's third quarter result of 18.23 Billion USD for the item "End Period Cash Flow" represents a decrease of -1.86 percent compared to it's second quarter result.
Also, Johnson & Johnson's third quarter result of 18.23 Billion USD for the item "End Period Cash Flow" represents a decrease of -8.75 percent compared to it's third quarter result of last year.
Looking again at the trailing twelve months series (TTM), Johnson & Johnson's third quarter result of 99.39 Billion USD for the item "End Period Cash Flow" represents a decrease of -1.73 percent compared to it's second quarter result.
Regarding the One-Year-Change of the series, the current value constitutes an increase of 7.81 percent compared to the value the year prior.
The 1 year change in percent is 7.81.
The 3 year change in percent is 110.17.
The 5 year change in percent is 57.82.
The 10 year change in percent is 95.69.
| Logo | Name | Market Cap (USD) |
|---|---|---|
![]() | Eli Lilly and Company - End Period Cash Flow | 905,699,262,464.00 |
![]() | AbbVie Inc - End Period Cash Flow | 399,570,305,024.00 |
![]() | Roche Holding AG - End Period Cash Flow | 317,433,206,677.55 |
![]() | AstraZeneca PLC - End Period Cash Flow | 280,205,508,085.11 |
![]() | Novartis AG - End Period Cash Flow | 255,096,620,580.91 |